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Abstract
Background: Pirfenidone is an antifibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF).
The drug is available for Polish patients with IPF since 2017. The PolExPIR study aimed to describe the real-world
data (RWD) on the Polish experience of pirfenidone therapy in IPF with respect to safety and efficacy profiles.
Methods: This was a multicentre, retrospective, observational study collecting clinical data of patients with IPF
receiving pirfenidone from January 2017 to September 2019 across 10 specialized pulmonary centres in Poland.
Data collection included baseline characteristics, pulmonary function tests (PFTs) results and six-minute walk test
(6MWT). Longitudinal data on PFTs, 6MWT, adverse drug reactions (ADRs), treatment persistence, and survival were
also collected up to 24 months post-inclusion.
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Results: A total of 307 patients receiving pirfenidone were identified for analysis. The mean age was 68.83 (8.13)
years and 77% were males. The median time from the first symptoms to IPF diagnosis was 15.5 (9.75–30) months
and from diagnosis to start of pirfenidone treatment was 6 (2–23) months. Patients were followed on treatment for
a median of 17 (12–22.75) months. Seventy-four patients (24.1%) required dose adjustments and 35 (11.4%) were
chronically treated with different than the full recommended dose. A total of 141 patients (45.92%) discontinued
therapy due to different reasons including ADRs (16.61%), death (8.79%), disease progression (6.51%), patient’s own
request (5.54%), neoplastic disease (3.91%) and lung transplantation (0.33%). Over up to 24 months of follow-up, the
pulmonary function remained largely stable. The median annual decline in forced vital capacity (FVC) during the
first year of pirfenidone therapy was −20 ml (−200–100) and during the second year was −120 ml (−340–30). Over a
study period, 33 patients (10.75%) died.
Conclusions: The PolExPIR study is a source of longitudinal RWD on pirfenidone therapy in the Polish cohort of
patients with IPF supporting its long-term acceptable safety and efficacy profiles and reinforce findings from the
previous randomised clinical trials and observational studies.
Keywords: Pirfenidone, Idiopathic pulmonary fibrosis, Real-world data, Efficacy, Safety, Poland
Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive, fibrotic lung disease, one of the most common
among a heterogeneous group of interstitial lung diseases
(ILDs). The natural history of the disease is characterized
by inevitable, progressive decline of lung function, reduc-
tion in exercise tolerance, quality of life and premature
death [1]. IPF is known to have outcomes worse than
many cancers, with a median survival of 3 to 5 years after
diagnosis, though the disease course varies significantly in
individuals [2, 3]. Two molecules, pirfenidone and ninte-
danib, have been shown to slow the disease progression
limiting the decline of lung function in patients with IPF
[4–6]. Both antifibrotics are recognized as an actual stand-
ard of pharmacological treatment of the disease [7]. Des-
pite early drug registrations in Europe (pirfenidone in
2011 and nintedanib in 2015), lack of reimbursement for
antifibrotics in Poland led to significant limitations in wide
access to antifibrotic therapy for Polish patients with IPF
[8]. Recent changes in the reimbursement policy for antifi-
brotics in Poland have resulted in much wider availability
of pirfenidone (since January 2017) and nintedanib (since
March 2018) for the treatment of Polish patients with IPF.
Randomised clinical trials (RCTs) on pirfenidone ther-
apy in IPF provided important information on its efficacy
and safety profiles. These trials proved that pirfenidone
treatment in IPF possesses acceptable safety, significantly
reduces the rate of decline of forced vital capacity (FVC)
and its use is associated with decreased mortality [9].
However, the follow-up period of pirfenidone RCTs lasted
only 52–72 weeks [4, 5, 10]. Moreover, strict inclusion and
exclusion criteria of RCTs may limit the possibility of
generalization of the results to the real-world setting clin-
ical practice. Therefore, real-world data (RWD) studies
based on data obtained outside the context of RCTs gen-
erated during routine clinical practice provide additional
pieces of evidence on the long-term efficacy and safety of
particular intervention in the broader real-world patients
populations.
Up to date, several RWD studies were published supple-
menting previous evidence of RCTs on the efficacy and
safety of pirfenidone in the treatment of heterogenous IPF
patients populations, however the scientific significance of
many of those studies suffer from a small number of pa-
tients included for analysis (<100 patients) [11–30]. More-
over, no data exist describing the clinical efficacy and
safety of long-term pirfenidone use in patients with IPF in
Poland.
The PolExPIR was a multicentre, retrospective, obser-
vational study collecting clinical data of patients with
IPF receiving pirfenidone from January 2017 to Septem-
ber 2019 across 10 specialized pulmonary centres in
Poland. The aim of the project was to provide for the
first time longitudinal data on clinical outcomes of pirfe-
nidone therapy in Polish cohort of patients with IPF
under real-world conditions.
Methods
Study cohort
In this study, a targeted population of Polish patients
with IPF receiving pirfenidone treatment in the setting
of therapeutic program refunded by the National Health
Fund (NHF) for patients with the mild-to-moderate dis-
ease was analysed. Main inclusion criteria for the NHF
therapeutic program were: a multidisciplinary team
(MDT) confident diagnosis of IPF according to 2011
international diagnostic guidelines [2], FVC above 50%
of predicted value and transfer factor of the lung for car-
bon monoxide (TLCO) above 30% of predicted value. All
patients eligible for NHF therapeutic program were re-
quired a regular follow-up with safety and efficacy as-
sessments. A mandatory re-evaluation of PFTs every 6
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months since drug initiation was demanded and disease
progression defined as a significant FVC decline (≥10%
of predicted value) over the first 12 months or over con-
secutive (after 12-months treatment) 6 months intervals
has been established as an exclusion criterion from con-
tinuation of pirfenidone therapy (drug stop rule). The
PolExPIR study enrolled all patients with IPF receiving
pirfenidone therapy for at least 12 months in the setting
of the NHF therapeutic program and those discontinu-
ing pirfenidone for any reason regardless of timing. The
study inclusion period lasted from January 2017 to Sep-
tember 2019. The local ethics committee needed no ap-
proval, as the study was retrospective, patients’ data
were anonymized and pirfenidone was already approved
in Poland.
Data collection
The PolExPIR study collected clinical data of patients
with IPF receiving pirfenidone across 10 specialized pul-
monary centres in Poland responsible for the diagnosis
and management of a broad spectrum of ILDs patients
and the supervision of antifibrotic therapy of patients
with IPF in the frame of NHF therapeutic program.
Retrospective clinical data collection included baseline
characteristics, data on diagnosis, previous treatment for
IPF, supplemental oxygen use, pulmonary function tests
(PFTs) results including spirometry and TLCO measure-
ments, and six-minute walk test (6MWT). Longitudinal
data on PFTs, 6MWT, adverse drug reactions (ADRs),
treatment persistence, and survival were also collected
up to 24months post-inclusion. To avoid the possible
bias in PFTs data interpretation associated with the use
of various reference equations and various reference
values, the measurements performed in different centres
were reported as absolute values and then expressed as
the percentages of predicted using the Global Lung
Function Initiative (GLI) reference values [31, 32].
Statistical analysis
Data were analysed using the R software for MacOS (R
Core Team, 2019, Vienna, Austria). Normality of data
distribution was tested with the Shapiro-Wilk test. Con-
tinuous data are expressed as mean with standard devi-
ation (SD) for normally distributed data or as median
with interquartile range (IQR) for non-normally distrib-
uted data. Categorical data are presented as absolute
numbers and relative frequencies. For the longitudinal
analysis, all available data were included. Data were ana-
lysed using the Wilcoxon signed-rank test. For the longi-
tudinal efficacy assessment of all the functional
parameters (FVC, TLCO and 6MWT) the difference be-
tween the initial and the last data available for the ana-
lysis was used. The dynamics of pulmonary function was
analysed as a difference between the timepoints specified
for each comparison separately and described in the re-
sults section. Additional subanalysis of the functional pa-
rameters changes in the 6-months intervals was also
performed. For the purpose of subanalysis of efficacy data
patients were divided based on the rate of changes in FVC
% of predicted (ΔFVC) in 6-months intervals into the fol-
lowing groups: significant improvement (ΔFVC >10%),
marginal improvement (10% ≥ ΔFVC>5%), stabilization
(+5% ≥ ΔFVC>-5%), marginal decline (−5% ≥ ΔFVC>-
10%), and significant decline (ΔFVC ≤ -10%). In terms of
the rate of changes in TLCO % of predicted (ΔTLCO) in 6-
months intervals, patients were divided into the following
groups: significant improvement (ΔTLCO >15%),
stabilization (+15% ≥ ΔTLCO>-15%), and significant de-
cline (ΔTLCO ≤ -15%). The graphs were performed using
GraphPad Prism 8 (GraphPad Software, La Jolla, San
Diego, CA, USA).
Results
Baseline characteristics
From January 2017 to September 2019 a total of 307 pa-
tients receiving pirfenidone in the setting of the NHF
therapeutic program across 10 participating sites were
identified for analysis. Patients were followed on pirfeni-
done treatment for a median of 17 months (12–22.75).
Summary of baseline characteristics of study participants
is shown in Table 1. The mean age at the onset of pirfe-
nidone treatment was 68.83 (8.13) years, and 77% of the
patients were males. The majority of patients were
former smokers (68.73%) however, more than 4% of IPF
patients (4.23%) were still actively smoking at the time
of enrolment for antifibrotic therapy. In almost 85% of
subjects IPF was diagnosed based on the presence of a
definite usual interstitial pneumonia (UIP) pattern on
the high-resolution computed tomography (HRCT) and
the remaining of patients required a combination of
HRCT and lung biopsy for the definite IPF diagnosis, see
Table 1. Seventeen patients with definite UIP pattern on
HRCT had undergone a surgical lung biopsy (SLB) prior
to the publication of 2011 diagnostic guidelines for IPF
[2]. Transbronchial lung biopsy (TBLB) was used in the
diagnostic work-up in as many as 9 patients but the re-
sults were diagnostic for UIP only in 2 cases. Transbron-
chial lung cryobiopsy (TBLC) was used for confirmation
of IPF diagnosis only in 2 patients. The median latency
period from the first symptoms to IPF diagnosis was
15.5 months (9.75–30) and from diagnosis to start of pir-
fenidone treatment was 6 months (2-23) . At baseline,
the median FVC was 77.08% of predicted (67.02–88.43)
and the median TLCO was 52.24% of predicted (42.56–
64.55). The mean partial arterial oxygen pressure (PaO2)
was 69 mmHg (n = 207). The median baseline distance
covered in the 6MWT was 490 m (400–540) (n = 165)
with a median of 7% desaturation (4-12) during the test.
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The majority of patients (95.76%) belonged to stage I
and II according to the multidimensional prognostic sta-
ging system for IPF (Gender, Age, and Physiology - GAP
index) [33]. Fifty-one patients (16.61%) were using home
oxygen therapy and 21 patients (6.84%) were using port-
able sources of oxygen at the onset of pirfenidone treat-
ment. The majority of patients (78.18%) had not been
treated for IPF before pirfenidone initiation, whereas ap-
proximately 10% of subjects had been treated in the past
Table 1 Characteristics of study participants
Number of patients, n (%) 307 (100)
City of Bydgoszcz, n (%) 15 (4.89)
City of Cracow (2 centres), n (%) 54 (17.59)
City of Gdansk, n (%) 26 (8.47)
City of Lodz, n (%) 40 (13.03)
City of Poznan, n (%) 9 (2.93)
City of Warsaw (2 centres), n (%) 75 (24.43)
City of Zabrze, n (%) 75 (24.43)
City of Zielona Gora, n (%) 13 (4.23)
Sex, male/female, n (%) 237 (77.2)/70
(22.8)
Age (years), mean (SD) 68.83 (8.13)
Smoking history
Never smokers, n (%) 72 (23.45)
Former smokers, n (%) 211 (68.73)
Active smokers, n (%) 13 (4.23)
No data, n (%) 11 (3.58)
Pack-years, median (IQR) 30 (15–40)
Comorbidities
Hypertension, n (%) 192 (62.54)
Coronary artery disease, n (%) 98 (31.92)
Hyperlipidaemia, n (%) 126 (41.04)
Atrial fibrillation, n (%) 39 (12.70)
Heart failure, n (%) 53 (17.26)
Gastroesophageal reflux disease, n (%) 114 (37.13)
Diabetes, n (%) 77 (25.08)
Emphysema, n (%) 51 (16.61)
Depression, n (%) 28 (9.12)
Obstructive sleep apnoea, n (%) 23 (7.49)
Benign prostate hypertrophy, n (%) 84 (27.36)
Neoplastic disease history, n (%) 24 (7.82)
Hypothyroidism, n (%) 27 (8.79)
Osteoarthritis of the spine, n (%) 24 (7.82)
Diagnosis of IPF
Radiologic UIP pattern, n (%) 260 (84.69)
Radiologic possible UIP pattern + SLB, n (%) 23 (7.49)
Radiologic possible UIP pattern + TBLC, n (%) 2 (0.65)
Radiologic inconsistent for UIP pattern + SLB, n (%) 3 (0.98)
Radiologic UIP pattern + SLB, n (%) 17 (5.54)
TBLB, n (%) 9 (2.93)
TBLB result diagnostic for UIP, n (%) 2/9 (22.22)
Time from first symptoms to diagnosis (months),
median (IQR)
15.5 (9.75–30)
Time from diagnosis to start of pirfenidone
therapy (months), median (IQR)
6 (2–23)
Table 1 Characteristics of study participants (Continued)
Pulmonary function
FEV1 (l), median (IQR) 2.29 (1.92–2.69)
FEV1 (% of predicted), median (IQR) 87.28 (71.88–
90.42)
FVC (l), median (IQR) 2.88 (2.35–3.39)
FVC (% of predicted), median (IQR) 77.08 (67.02–
88.43)
TLCO (mmol/min/kPa), median (IQR) 4.02 (3.2–5.03)
TLCO (% of predicted), median (IQR) 52.24 (42.56–
64.55)
Blood oxygenation
SpO2 at rest (%), median (IQR) 95 (93–96)
PaO2 at rest (n = 207), (mmHg), mean (SD) 69.06 (9.75)
6MWT
Distance (n = 165), (meters), median (IQR) 490 (400–540)
Desaturation, (Δ%), median (IQR) 7 (4–12)
GAP score, median (IQR) 3 (3–4)
GAP index:
Stage I, n (%) 170 (55.37)
Stage II, n (%) 124 (40.39)
Stage III, n (%) 13 (4.23)
Oxygen therapy
Home oxygen therapy, n (%) 51 (16.61)
Ambulatory oxygen therapy (portable sources), n
(%)
21 (6.84)
IPF treatment in the past before initiation of pirfenidone
No treatment, n (%) 240 (78.18)
CS, n (%) 33 (10.75)
NAC, n (%) 1 (0.33)
CS + NAC, n (%) 0 (0)
CS + NAC + AZA, n (%) 1 (0.33)
Clinical trial, n (%) 32 (10.42)
Abbreviations: UIP usual interstitial pneumonia, SLB surgical lung biopsy, TBLC
transbronchial lung cryobiopsy, TBLB transbronchial lung biopsy, FEV1 forced
expiratory volume in 1 s, FVC forced vital capacity, IPF idiopathic pulmonary
fibrosis, TLCO transfer factor of the lung for carbon monoxide, SpO2
percutaneous oxygen saturation, PaO2 partial pressure of arterial oxygen,
6MWT six-minute walk test, GAP gender, age, and 2 physiology variables (FVC
and TLCO), CS corticosteroids, NAC N–acetylcysteine, AZA azathioprine
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with corticosteroids (CS) or participated in various clin-
ical trials.
Tolerability, safety and drug persistence assessment
Table 2 summarizes the tolerability and ADRs of pirfeni-
done treatment. Seventy-four patients (24.1%) required
dose adjustments including intermittent drug interrup-
tion and/or reduction of dosing to continue adherence
to treatment and 35 (11.4%) were chronically treated
with a different than the full recommended dose. The
most frequent ADRs were fatigue (35.83%), decreased
appetite (34.2%), weight loss (32.57%), cough (28.66%),
nausea (24.43%), dyspepsia (23.13%), skin rash (18.89%)
and photosensitivity reactions (17.59%).
Over the median time of 17 months (12–22.75) of pir-
fenidone exposition, a total of 141 patients (45.9%) dis-
continued therapy due to different reasons including
ADRs (16.6%), death (8.7%), disease progression (6.5%),
patient’s own request (5.5%), diagnosis of neoplastic dis-
ease (3.9%) and lung transplantation (0.3%), see Table 3.
Among ADRs leading to treatment discontinuation the
most common were gastrointestinal ADRs (51%) and
skin-related ADRs (33%), see Fig. 1. Over a study period,
33 patients (10.75%) died. IPF-related death occurred in
21 patients (63.64%), cardiovascular-related death in 2
patients (6.06%), neoplastic disease-related death in 3 pa-
tients (9.09%) and unknown or other cause of death in 7
patients (21.21%).
Longitudinal efficacy assessment
The median annual decline in forced vital capacity
(FVC) during the first year of pirfenidone treatment was
−20 (−200–100) ml (n = 226) and during the second year
was −120 (−340–30) ml (n = 61). The median change
from baseline in % of predicted FVC was −0.68%
(−5.27–2.61) at month 12 and −5.42% (−8.90–0.90) at
month 24, see Fig. 2a.
Meanwhile, the median TLCO decline was −0.34
(−0.83–0.14) mmol/min/kPa in the first year of pirfeni-
done treatment (n = 222) and −0.57 (−1.11–0.25) mmol/
min/kPa in the second year of therapy (n = 61). The me-
dian change from baseline in % of predicted TLCO was
−4.94% (−11.18–1.65) at month 12 and −8.18% (−18.46–
0.67) at month 24, see Fig. 2b. The median change from
baseline in 6MWT distance during pirfenidone treat-
ment was 0.00 (−35.5–34.00) meters (n = 93) at month
12 and −31.5 (−67.00–7.5) meters (n = 24) at month 24,
see Fig. 2c.
The longitudinal analysis of changes in FVC % of pre-
dicted and TLCO % of predicted in 6-months intervals is
shown in Fig. 3 and Table 4. The significant differences
were noted in the rate of decline of FVC % of predicted
in the second year of pirfenidone therapy, namely be-
tween 12 and 18months interval as well as between 18
and 24months interval compared to the first 0–6
months interval (p < 0.05). No significant difference was
noted in the rate of decline of TLCO % of predicted in
the interval analysis during 24months of pirfenidone
treatment.
The 6-months interval subanalysis of FVC and TLCO
data is shown in Table 5.
Longitudinal change in FVC and TLCO varied among
the individual cases in our study. Change in FVC in the
majority of patients (range of 61–68% depending on the
interval analysed) was stable, and only in the minority of
them (range 4–14% and 0–6%) showed marginal or
significant improvement, respectively. Marginal or
significant decline was observed likewise only in the mi-
nority of patients (range 12–29% and 2–7%, respectively).
Table 2 Tolerability and adverse drug reactions (ADRs) of
pirfenidone therapy
Full dose treatment, n (%) 272 (88.6)
Different than full dose
treatment, n (%)
35 (11.4)
Intermittent drug interruption
and/or reduction of dosing, n (%)
74 (24.1)
ADRs
Nausea, n (%) 75 (24.43)
Decreased appetite, n (%) 105 (34.2)
Diarrhoea, n (%) 33 (10.75)
Vomiting, n (%) 15 (4.89)
Dyspepsia, n (%) 71 (23.13)
Loss of weight, n (%) 100 (32.57)
Cough, n (%) 88 (28.66)
Fatigue, n (%) 110 (35.83)
Dizziness, n (%) 42 (13.68)
Skin rash, n (%) 58 (18.89)
Photosensitivity, n (%) 54 (17.59)
Elevated liver enzymes, n (%) 9 (2.93)
Sleep disturbances, n (%) 49 (15.96)
Other, n (%) 36 (11.73)
Abbreviations: ADRs adverse drug reactions
Table 3 Treatment persistence
Pirfenidone exposition, (months), median (IQR) 17 (12–22.75)
Reasons for treatment discontinuation
ADRs, n (%) 51 (16.61)
Disease progression, n (%) 20 (6.51)
Death, n (%) 27 (8.79)
Patient’s decision, n (%) 17 (5.54)
Lung transplantation, n (%) 1 (0.33)
Neoplastic disease, n (%) 12 (3.91)
Other, n (%) 13 (4.23)
Abbreviations: ADRs adverse drug reactions
Majewski et al. BMC Pulmonary Medicine          (2020) 20:122 Page 5 of 12
In terms of change of TLCO values longitudinal evaluation
confirmed stabilization in the majority of patients (range
85–91% depending on the interval analysed) and signifi-
cant improvement or significant decline only in the mi-
nority of them (range 2–6% and 7–11%, respectively).
The graphical presentation of the interval subanalysis
of FVC and TLCO data is shown in Figs. 4 and 5.
Discussion
In the present study, we examined retrospectively longi-
tudinal data on clinical outcomes of pirfenidone therapy
in patients with IPF in Poland under real-world condi-
tions. The main findings of our study confirm the long-
term acceptable safety and tolerability profiles of pirfeni-
done in the treatment of IPF and show that the large
percentage of patients with IPF receiving pirfenidone ex-
perience functional stabilization and in the minority of
them a functional improvement may be observed over
up to 24 months of follow-up. Moreover, the Polish
RWD on the pirfenidone safety and efficacy in IPF are in
the line with the results of previous RCTs and other
smaller retrospective and observational studies under-
taken to date. To sum up, the PolExPIR study is a valu-
able source of evidence gathered from the large
representative real-world population of patients with IPF
in Poland.
Pirfenidone is an oral antifibrotic drug which has been
licensed for the treatment of patients with mild-to-
moderate IPF in Europe (2011) and in the United States
(2014) and is currently conditionally recommended in
the international clinical practice treatment guidelines
[7]. Nevertheless, lack of reimbursement policy for anti-
fibrotics in Poland resulted in very limited access to
antifibrotic therapy for Polish patients with IPF, which
has been clearly demonstrated by the real-life survey
conducted among the Polish pulmonologists in 2016 [8].
Recently, changes in the reimbursement policy for
antifibrotics in Poland have led to the wider availability
of pirfenidone since January 2017 for the treatment of
Polish patients with IPF [34]. The drug has become
available in the frame of therapeutic program refunded
by the NHF for patients with the mild-to-moderate dis-
ease based on the inclusion criteria similar to those used
for the phase III pirfenidone RCT, namely the ASCEND
study [5]. As a consequence of such therapeutic program
eligibility criteria, the baseline demographic and clinical
characteristics of patients in the PolExPIR cohort were
similar to those from the ASCEND trial [5]. In both co-
horts, patients had a mean age of 68 years, close to 80%
of them were males, and about two-thirds were former
smokers. However, slightly higher percentage of patients
in the ASCEND trial had a definite UIP pattern in
HRCT compared to the PolExPIR cohort (95% vs 90%,
respectively), and the median baseline value of FVC % of
predicted was lower in the ASCEND trial compared to
the PolExPIR (68% vs 77%, respectively). Our study co-
hort represented real-world clinical practice population
of patients with IPF with a number of coexisting comor-
bidities and drug therapies which could potentially ex-
clude at least a part of them from participation in the
RCTs like the ASCEND study. Lack of strict selection of
patients for therapy and a more pragmatic approach is
typical for real-world setting clinical practice. Therefore,
the results of the PolExPIR study can be considered to
be more representative of daily clinical practice than the
results of RCTs.
Fig. 1 Adverse drug reactions (ADRs) categories leading to pirfenidone treatment discontinuation
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Our analysis of drug tolerability, safety assessment,
and treatment persistence confirmed well-established
safety and tolerability profiles of pirfenidone [35–37].
The ADRs observed in our study were similar to those
reported in pirfenidone RCTs and no new long-term use
safety signals have emerged. Fatigue along with gastro-
intestinal and skin-related ADRs were among the most
common adverse events recorded in our study. Interest-
ingly, the most frequent ADR in the PolExPIR cohort
was fatigue occurring in 35.83% of patients during the
study follow-up period. Noted frequency of fatigue dur-
ing pirfenidone treatment is significantly higher than the
incidence of fatigue reported in RCTs, namely CAP-
ACITY (7%) and ASCEND (21%) trials. However, even a
slightly higher incidence of fatigue (38.9%) than observed
in the PolExPIR cohort has been reported in the
Fig. 2 Change over 24months of follow-up in: a) FVC % of
predicted; b) TLCO % of predicted; c) 6MWT distance. Change from
baseline was calculated as a follow-up time point value minus the
baseline value, therefore negative value indicates a decrease from
baseline. Data are presented as median (IQR) values. Abbreviations:
FVC – forced vital capacity, TLCO – transfer factor of the lung for
carbon monoxide, 6MWT – six-minute walk test
Fig. 3 Longitudinal 6-months interval change during pirfenidone
treatment in a) FVC % of predicted (ΔFVC); b) TLCO % of predicted
(ΔTLCO). Data are presented as median (IQR) values. Notes: *p < 0.05,
**p < 0.01. Abbreviations: FVC – forced vital capacity, TLCO – transfer
factor of the lung for carbon monoxide
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nationwide observational study undertaken in Denmark
[17]. The ADRs led to permanent treatment discontinu-
ations in 16.61% of Polish patients which, despite me-
dian longer drug exposition, is in good agreement with
the rates of pirfenidone discontinuations due to ADRs
reported in the CAPACITY study (15%) [4] and the AS-
CEND study (14.4%) [5]. Although, pirfenidone treat-
ment discontinuation rates due to ADRs reported in the
previous observational RWD studies vary significantly in
the range of 1.7 to 31.8% [12, 14, 17, 19, 25–28]. The
majority of discontinuations in our study related to
ADRs (84%) were gastrointestinal and skin-related which
is consistent with previous pirfenidone tolerance data
[35–37]. No patient experienced ADRs with a fatal out-
come. Treatment discontinuation rates in the PolExPIR
cohort due to death (8.79%) or disease progression
(6.51%) were slightly lower than in the recently pub-
lished report of the French Ancillary Study (FAS) of
PASSPORT registry (11.5 and 10.9% respectively) despite
similar median duration of exposure to pirfenidone in
both studies (17 vs 16.3 months, respectively) [26]. Sur-
prisingly, only one patient in the PolExPIR cohort
(0.33%) discontinued pirfenidone treatment due to lung
transplantation. In the recently published results of an
observational study of patients with IPF treated with pir-
fenidone in Belgium and Luxembourg (PROOF registry)
the lung transplant rate for all patients during a study
follow-up of 24 months was 5.6% (13 out of 233 pa-
tients) [28]. This finding confirms that improvement in
cooperation between pulmonary centres and transplant-
ation units in Poland is crucial for optimal patients out-
comes in this matter.
Due to retrospective character of the PolExPIR study,
it has not included any specific survival analysis. How-
ever, we did obtain valuable information on patients
who died during the study follow-up. Our mortality data
confirm that lung disease itself is the most common
cause of death in IPF, next to cardiovascular and neo-
plastic disease-related deaths. These observations are in
line with a recently published analysis of causes of death
in patients with IPF in Finland [38].
Over 24months of follow-up in the PolExPIR cohort
PFTs values remained generally stable. Interestingly, me-
dian annual FVC decline of −20ml in the first year and
−120ml in the second year of pirfenidone treatment ob-
served in the PolExPIR was even less than that noted in
the ASCEND trial, in which mean decline from baseline
in FVC was −235ml in the pirfenidone group over 52
weeks [5]. However, in the real-world study reporting clin-
ical experience of the long-term use of pirfenidone in the
large cohort of Japanese patients with IPF the mean de-
cline of FVC was −30ml and −158ml in the first and sec-
ond year of therapy, respectively [29], which is in good
agreement with our study results. Moreover, a study of
Tzouvelekis et al. [19] and a recent study of Vietri et al.
[30] reported similar findings of worsening of FVC decline
rate after 12months of pirfenidone treatment. Taken to-
gether, ours and others data may suggest that long-term
efficacy of pirfenidone in IPF may differ according to the
duration of treatment. On another note, a recent observa-
tional study of Czech IPF cohort from EMPIRE registry
reported a substantial stability of FVC decline rate even
after 2 years of pirfenidone therapy [39]. Given the fact,
that PolExPIR and other RWD studies of long-term
Table 5 Patient distribution in relation to longitudinal 6–months interval change in FVC % of predicted (ΔFVC) and TLCO % of
predicted (ΔTLCO)
ΔFVC 0–6 months 6–12months 12–18months 18–24 months
significant improvement (ΔFVC >10%)
marginal improvement (10%≥ ΔFVC>5%)
stabilization (+5%≥ ΔFVC>-5%)
marginal decline (−5%≥ ΔFVC>-10%)
significant decline (ΔFVC≤ -10%)
n
14 (5.6%)
35 (14%)
152 (60.8%)
31 (12.4%)
18 (7.2%)
250
7 (3.1%)
25 (11.2%)
152 (68.2%)
28 (12.6%)
11 (4.9%)
223
4 (2.9%)
9 (6.6%)
89 (65%)
31 (22.6%)
4 (2.9%)
137
0 (0%)
2 (3.6%)
36 (65.5%)
16 (29.1%)
1 (1.8%)
55
ΔTLCO 0–6 months 6–12months 12–18months 18–24 months
significant improvement (ΔTLCO >15%)
stabilization (+15%≥ ΔTLCO>-15%)
significant decline (ΔTLCO≤ -15%)
n
4 (1.7%)
210 (87.1%)
27 (11.2%)
241
4 (1.8%)
197 (90.8%)
16 (7.4%)
217
8 (5.7%)
119 (85%)
13 (9.3%)
140
1 (1.6%)
55 (87.3%)
7 (11.1%)
63
Abbreviations: FVC forced vital capacity, TLCO transfer factor of the lung for carbon monoxide
Table 4 Longitudinal 6–months interval change during pirfenidone treatment in FVC % of predicted (ΔFVC) and TLCO % of
predicted (ΔTLCO). Data are presented as median (IQR) values
0–6 months 6–12 months 12–18 months 18–24 months p (6–12 vs 0–6) p (12–18 vs 0–6) p (18–24 vs 0–6)
ΔFVC 0 (−3.69–3.93) −1.06 (−3.90–2.90) −1.84 (−5.04–1.37) −2.10 (−5.73–1.63) 0.13 < 0.01 < 0.05
ΔTLCO −2.02 (−7.81–3.09) −2.11 (−6.79–1.96) −2.17 (−8.07–1,84) −3.56 (−8.77–1.12) 0.98 0.24 0.22
Abbreviations: FVC forced vital capacity, TLCO transfer factor of the lung for carbon monoxide
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Fig. 4 Percentage of patients with IPF experiencing significant (ΔFVC >10%) or marginal (10%≥ ΔFVC>5%) improvement, stabilization (+5%≥
ΔFVC>-5%), and marginal (−5%≥ ΔFVC>-10%) or significant (ΔFVC≤ -10%) decline based on the rate of changes of FVC % of predicted (ΔFVC) in
the 6-months intervals during pirfenidone treatment
Fig. 5 Percentage of patients with IPF experiencing significant (ΔTLCO >15%) improvement, stabilization (+15%≥ ΔTLCO>-15%), and significant
(ΔTLCO≤ − 15%) decline based on the rate of changes of TLCO % of predicted (ΔTLCO) in the 6-months intervals during pirfenidone treatment
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pirfenidone use in IPF reporting worsening of FVC decline
after 12months of pirfenidone treatment are retrospective,
their results should be interpreted with caution. There-
fore, a well-designed, prospective, longitudinal study
undertaken in the large IPF population is needed to clarify
whether pirfenidone maintains its efficacy over a follow-
up of more than 1 year.
The median change from baseline in % of predicted
FVC was −0.68% at month 12 and −5.42% at month 24,
which is definitely below the threshold of 10% decline
regarded as a marker of significant disease progression.
A similar observation was noted for the median change
from baseline in % of predicted TLCO of −4.94% at
month 12 and −8.18% at month 24, which is also below
clinically significant deterioration threshold of 15% de-
cline [2]. Longitudinal evaluation of PFTs change over
the study follow-up, including 6-months interval analysis
of data, confirmed that the majority of patients obtained
disease stabilization under pirfenidone treatment and
only minority of them improved or declined in terms of
PFTs results.
The decline in the 6MWT distance over the study
follow-up was likewise promising. We observed no
change in the 6MWT distance over the first year of
treatment and the median change of only −31.5 m after
24 months from the initiation of pirfenidone therapy.
However, the number of patients with available data for
analysis was low. For comparison, in the phase III pirfe-
nidone trials CAPACITY 004 and 006 the mean change
in 6MWT distance based on pooled data analysis was
−52.8 m in the pirfenidone group over 72 weeks [4].
Interestingly, a recently published analysis of FAS of
PASSPORT registry of IPF cohort reported the mean
change from baseline in 6MWT distance of 8.6 and 3.1
m at months 12 and 24, respectively [26]. It is likely, that
both the PolExPIR and the FAS of PASSPORT registry
results could suffer from bias related to a low number of
patients with available data for longitudinal analysis of
change in 6MWT distance.
However, changes in 6MWT distance after 12 and 24
months of pirfenidone therapy, observed in our cohort,
are concordant with the finding of difference in FVC de-
cline in the first and the second year of follow-up, which
is supporting validity of our study results.
The main strengths of the PolExPIR study are non-
sponsored, multicentre design and analysis of data col-
lected from one of the largest real-world population of
patients with IPF treated with pirfenidone to date. Very
few studies undertaken worldwide provide such data
from the cohorts of more than 300 patients [18, 27, 29,
39]. The median pirfenidone exposition in our study was
longer than in RCTs and most of the observational stud-
ies published to date. Lack of strict inclusion and exclu-
sion criteria characterizing RCTs allowed for a collection
of data more representative for the broad population of
patients with IPF typical for the real-world setting clin-
ical practice. A broader patients population and a longer
median follow-up may record a more complete picture
of pirfenidone safety and effectiveness than RCTs.
The findings of our study should be considered in the
context of several limitations. The most important one
is the retrospective nature of the multicentre observa-
tional study. It is of note, that study participating centres
were selected based on their experience in the manage-
ment of patients with IPF, although the collection of
clinical data and PFTs or 6MWT administration prac-
tices may have differed across those sites. This could
lead to both missing data and reporting bias. Due to the
study design, patients discontinuing treatment were
excluded from longitudinal follow-up which may have
induced bias in the reporting of survival data. The
assessment of effectiveness is limited by a single-arm de-
sign and a lack of the control group. Our study efficacy
data could be strengthened by pre-treatment and post-
treatment comparison of the rate of decline of FVC and
TLCO, although this was not possible due to a small
number of available previous PFTs results. Despite the
above limitations, in our opinion, obtained results pro-
vide confidence since safety, tolerability and efficacy data
are in line with that of pirfenidone RCTs and other real-
world observational studies.
Conclusions
In conclusion, the PolExPIR study provides for the first
time the real-world setting data on the longitudinal clin-
ical outcomes of pirfenidone therapy in the large cohort
of patients with IPF in Poland. Over up to 24months of
follow-up, the pulmonary function of patients with IPF
receiving pirfenidone remained largely stable and ADRs
led to permanent treatment discontinuations in 16.61%
of patients. Taken together, the main study findings con-
firm pirfenidone’s long-term acceptable safety and effi-
cacy profiles and reinforce conclusions from the
previous RCTs and observational studies.
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